Abstracts tagged "ACPA"

Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Richard Meehan¹, Eric Hoffman², David Muram³, Barbara Goldstein⁴, Jim Crooks⁵ and Pearlanne Zelarney⁶, ¹MEDICINE, National Jewish Health, Denver, CO, ²Medicine/Rheumjatology, National Jewish Health, denver, CO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…
Abstract Number: 964 • 2015 ACR/ARHP Annual Meeting
Neutrophil Extracellular Traps Are Not Only Targets for ACPA-Positive IgG from Rheumatoid Arthritis Patients but Also Directly Trigger Pro- and Anti-Inflammatory Effects Partly Mediated By the C1q Complement Protein
Matthieu Ribon¹, Sarra Seninet¹, Katarzyna Matyja¹, Mireille Sebbag², Cyril Clavel², Julie Mussard¹, Guy Serre², Marie-Christophe Boissier³ and Patrice Decker¹, ¹Inserm UMR 1125, Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²University of Toulouse, UMR 5165 CNRS-1056 Inserm, Toulouse, France, ³Rheumatology Department, Avicenne Hospital, AP-HP, Bobigny, France
Background/Purpose: Activated neutrophils (PMN) form neutrophil extracellular traps (NET). Those structures are expelled chromatin fibers composed of DNA and associated proteins. The process, NETosis, is…
Abstract Number: 2688 • 2015 ACR/ARHP Annual Meeting
Socioeconomic Status, Ethnicity/Race, and Autoantibody Status in Rheumatoid Arthritis
Mercedes Quinones¹, Sharon Dowell¹, Gail S. Kerr², Christopher Swearingen³, Yusuf Yazici⁴, Luis Espinoza⁵, Ignacio Garcia-Valladares⁶, Edward L. Treadwell⁷, Theresa Lawrence Ford⁸, Yvonne Scherrer⁹, Angelia Mosley-WIlliams¹⁰, Rodolfo Perez Alamino¹¹, Akgun Ince¹², John Amatruda¹³ and Jorge Flautero Arcos¹⁴, ¹Howard University Hospital, Washington, DC, ²Washington DC VAMC, Georgetown University Hospital, Howard University Hospital, Washington, DC, ³Pediatrics & Biostatistics, University of Arkansas, Little Rock, AR, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine-Section of Rheumatology, LSU Medical Center, New Orleans, LA, ⁶Immunology & Rheumatology, Hospital General de Occidente, Zapopan, Jalisco, Mexico, ⁷Dept Medicine Div of Rheum, E Carolina Univ Sch of Med, Greenville, NC, ⁸North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁹Center for Rheumatology & Immunology Arthritis, Fort Lauderdale, FL, ¹⁰John Dingell VAMC, Detroit, MI, ¹¹Rheumatology, Lousiana State University and LSU Medical Center, New Orleans, LA, ¹²Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹³Rheumatology, Howard University, Washington, DC, ¹⁴Rheumatology, Howard University Hospital, Washington, DC
Background/Purpose: Ethnic disparities in outcomes of RA patients have been attributed to delayed presentation to specialty care and access to DMARDs, greater disease burden, and…
Abstract Number: 965 • 2015 ACR/ARHP Annual Meeting
Crystal Structure of Porphyromonas Gingivalis peptidylarginine Deiminase: Implications for Autoimmunity in Rheumatoid Arthritis
Anna B. Montgomery¹, Jolanta Kopec², Leela Shresha², Marie-Laetitia Thezenasc³, Nicola A. Burgess-Brown², Roman Fischer³, Wyatt W. Yue² and Patrick J. Venables¹, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Structural Genomics Consortium, University of Oxford, Oxford, United Kingdom, ³Target Discovery Institute, University of Oxford, Oxford, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are the main autoantibody system in rheumatoid arthritis (RA), and due to high sensitivity and specificity testing using the anti-CCP2…
Abstract Number: 2700 • 2015 ACR/ARHP Annual Meeting
Trabecular Thinning in Metacarpophalangeal Joints of Anticitrullinated Peptide Antibody Positive Patients with Arthralgia
Kresten Krarup Keller¹, Jesper Skovhus Thomsen², Kristian Stengaard-Pedersen¹, Andreas Wiggers Nielsen¹, Berit Schiøtz-Christensen³, Lone Svendsen⁴, Merete Graakjær⁵, Peter Mosborg Pedersen⁶, Barbara Unger⁷, Bente Langdahl⁸ and Ellen-Margrethe Hauge¹, ¹Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Aarhus University, Aarhus, Denmark, ³Spine Centre of Southern Denmark, Middelfart, Denmark, ⁴Private Practice in Rheumatology, Skanderborg, Denmark, ⁵Clinic of Rheumatology Aarhus, Aarhus, Denmark, ⁶Randers Hospital, Randers, Denmark, ⁷Horsens Hospital, Horsens, Denmark, ⁸Endocrinology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is characterized by synovitis leading to bone erosions and joint destruction, but little is known about bone structure in the joints…
Abstract Number: 1206 • 2015 ACR/ARHP Annual Meeting
Presence of ACPA in a Large (>40.000) Population Based Cohort from the Netherlands
Elisabeth Brouwer¹, Suzanne Arends², Hendrika Bootsma¹, Caroline Roozendaal³, Pieter C Limburg⁴, Fiona Maas¹, René E. M. Toes⁵, T. W. J. Huizinga⁶, LA Trouw⁷ and Annemirthe Van Zanten¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁴Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) status provides important information regarding the diagnosis and prognosis of Rheumatoid Arthritis (RA). By using samples from blood bank donors…
Abstract Number: 2707 • 2015 ACR/ARHP Annual Meeting
An in Vitro Bovine Bone Chip Model with Micro-CT: A Model for the Assessment of Autoantibody Mediated Bone Resorption
Manpreet Kaur Sethi¹, Anand Dusad¹, Andy Hollins², Carlos D. Hunter³, Michael J. Duryee³, Ted R. Mikuls², Geoffrey M. Thiele⁴ and Ellen M. Gravallese⁵, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Lazare Research Bldg Ste 223, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are specific to rheumatoid arthritis (RA) and are associated with disease severity. Although ACPAs are associated with disease progression, mechanisms…
Abstract Number: 1216 • 2015 ACR/ARHP Annual Meeting
The Clinical and Ultrasonographic Presentation of Seronegative RA Is More Severe Compared to Seropositive RA in an Inception Cohort of DMARD-Naïve Patients Classified According to the 2010 ACR/EULAR Criteria
Lena B. Nordberg¹, Siri Lillegraven¹, Elisabeth Lie¹, Anna-Birgitte Aga², Inge C Olsen², Hilde Berner Hammer³, Till Uhlig¹, Désirée van der Heijde⁴, Tore K. Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC Study Group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The development of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis (RA) has led to a redefinition of the patient population, including classification of…
Abstract Number: 2711 • 2015 ACR/ARHP Annual Meeting
The Lung Microbiome in Rheumatoid Arthritis and Associated Local/Systemic Autoimmunity
Jose U. Scher¹, Vijay Joshua², Carles Ubeda³, Alejandro Artacho³, Leopoldo Segal⁴ and Anca I Catrina⁵, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Cmm L8:04, Karolinska Institutet, Stockholm, Sweden, ³Institute for Research in Public Health, Valencia, Spain, ⁴Medicine, Pulmonay Division, NYU School of Medicine, New York City, NY, ⁵Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disorder in which several genetic and environmental factors play a role. Recent data suggest that the gut…
Abstract Number: 1435 • 2015 ACR/ARHP Annual Meeting
Central Pain Sensitization in Rheumatoid Arthritis – Role of ACPA?
Katarzyna Rogoz¹, Teresa Fernandez Zafra¹, Catia Cerqueira², Per Johan Jakobsson³, Katalin Sandor⁴, Erwan Le Maître⁵, Magnus LA. Andersson⁶, K. Lundberg⁷, Camilla Svensson⁴ and Jon Lampa⁸, ¹Physiology and pharmacology, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Dep of Neurology, Karolinska Institute, Stockholm, Sweden, ⁷Karolinska Institute, Stockholm, Sweden, ⁸Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Chronic pain continues to be a significant problem for patients with rheumatoid arthritis (RA), even when the disease is medically controlled or in remission.…
Abstract Number: 3100 • 2015 ACR/ARHP Annual Meeting
Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis
Maximilian F. Konig¹, Jon Giles², Peter A. Nigrovic³ and Felipe Andrade¹, ¹Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Antibodies against RA33 (hnRNP A2/B1) were one of the earliest antigen specificities identified in rheumatoid arthritis (RA). Unlike the erosive disease associated with anti-citrullinated…
Abstract Number: 1510 • 2015 ACR/ARHP Annual Meeting
The Association Between HDL Cholesterol Efflux Capacity, Citrullinated ApoA1 and Anti-Citrullinated ApoA1 Antibodies in Rheumatoid Arthritis
Katherine Liao¹, Jing Cui¹, Christopher Rhodes², Lauren J. Lahey², Martin Playford³, I-Hsin Kuo¹, Michelle Frits¹, Christine Iannaccone¹, Jonathan S. Coblyn⁴, Michael Weinblatt¹, Nancy Shadick⁵, Nehal N. Mehta³ and Jeremy Sokolove², ¹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³NHLBI, National Institutes of Health, Bethesda, MD, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: High density lipoprotein (HDL) cholesterol efflux capacity measures how well HDL particles remove cholesterol from lipid-laden macrophages, such as those found in atherosclerotic plaques. …
Abstract Number: 3172 • 2015 ACR/ARHP Annual Meeting
Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez², Ana M. Ortiz Garcia², Eugenio Escolano³, Teresa Velasco¹, Elena García², Esther Vicente-Rabaneda², Alberto Garcia-Vadillo⁴, Rosario Garcia-Vicuña⁴, Isidoro González-Alvaro*² and Santos Castañeda*², ¹Rheumatology, H.U La Princesa, Madrid, Spain, ²Rheumatology, H.U. La Princesa, Madrid, Spain, ³Radiology Department, H.U La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Recently it has been described that anti citrullinated protein antibodies (ACPA) can induce differentatiomn and activation of osteoclasts even before arthritis onset (1,2). The…
Abstract Number: 1594 • 2015 ACR/ARHP Annual Meeting
No Association of Anti-Citrullinated Peptide Antibodies with Coronary Artery Calcification in Two Rheumatoid Arthritis Cohorts without Clinical Cardiovascular Disease
Laura Geraldino-Pardilla¹, Jon T. Giles², Jeremy Sokolove³, Afshin Zartoshti⁴, WH Robinson⁵ and Joan M. Bathon⁶, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Citrullinated proteins have been found in atherosclerotic plaques. However, contradictory results currently exist regarding the association of anti-citrullinated peptide antibodies (ACPAs) with coronary artery…
Abstract Number: 3253 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Antibodies to Cyclic Citrullinated Peptide in Two Prospective Early Rheumatoid Arthritis Cohorts 10 Years Apart
Alf Kastbom¹, Michael Ziegelasch¹, Ingrid Thyberg¹, Birgir Arge², Klara Martinsson¹, Olle Svernell³, Åsa Häggström⁴, Per Salomonsson⁵, Britt-Marie Nyhäll-Wåhlin⁶, Sören Transö⁷, Claudia Jacobs⁸ and Thomas Skogh¹, ¹IKE/Rheumatology, Linköping University, Linköping, Sweden, ²Rheumatology clinic, Eskilstuna Hospital, Eskilstuna, Sweden, ³Rheumatology Dpt, Västervik Hospital, Västervik, Sweden, ⁴Rheumatology clinic, Kalmar Hospital, Kalmar, Sweden, ⁵Rheumatology Clinic, Örebro University Hospital, Örebro, Sweden, ⁶Department of Rheumatology, Falun Hospital, Falun, Sweden, ⁷Rheumatology Clinic, Ryhov Hospital, Jönköping, Sweden, ⁸Rheumatology Dept, Oskarshamn Hospital, Oskarshamn, Sweden
Background/Purpose: Antibodies to cyclic citrullinated peptides (anti-CCP) associate with a more severe rheumatoid arthritis (RA) disease course, and therefore have influence on therapeutic decisions. By…

« Previous Page
1
…
5
6
7
8
9
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].